Physician profile
Suzanne Hanle
NPI 1053836890
$3,324.44
in general payments reported to CMS, 2019-2025
20 companies · $634 in 2025
The $634 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $901 · 2024: $1,790 · 2025: $634.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,310 · Education: $14.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,309.59 |
| Education | $14.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $625.62 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $403.30 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Jazz Pharmaceuticals INC. | $328.43 | 2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $268.13 | 2023-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $243.69 | 2023-2025 | Ingrezza |
| Alkermes, INC. | $212.03 | 2023-2025 | Aristada, Lybalvi, Vivitrol |
| Braeburn INC. | $154.39 | 2023-2025 | Brixadi |
| Indivior INC. | $149.69 | 2023-2025 | Sublocade, Perseris |
| Axsome Therapeutics, INC. | $145.83 | 2024-2025 | Auvelity |
| Avadel Cns Pharmaceuticals, LLC | $134.77 | 2024 | Lumryz |
| E.R. Squibb & Sons, L.L.C. | $129.45 | 2025 | Cobenfy |
| Tempus Ai, INC | $116.56 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $110.17 | 2024-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $87.90 | 2023-2025 | Trintellix |
| Uswm, LLC | $71.56 | 2023 | Zimhi, Lucemyra |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.46 | 2024 | |
| Lundbeck LLC | $33.19 | 2024-2025 | Rexulti |
| Impel Pharmaceuticals INC. | $27.83 | 2023 | Trudhesa |
| Bioxcel Therapeutics, INC. | $22.44 | 2023 | Igalmi |
| Supernus Pharmaceuticals, INC. | $19.00 | 2024 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzanne Hanle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.